Merck has halted deliveries of its Gardasil vaccine to China, impacting its sales forecast for 2025. The company anticipates sales for 2025 to range between $64.1 billion and $65.6 billion, below analysts' projections of $67.31 billion. Gardasil sales dropped by 17% to $1.55 billion in the final quarter of the previous year. Merck's outlook is shaped by the necessity to counterbalance losses from its cancer treatment Keytruda, which is set to lose exclusivity in 2028.